Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDLEY: nirsevimab versus palivizumab in high-risk infants entering an RSV season
jRCT2080224799Phase 3Completed
- Sponsor
- MedImmune
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of nirsevimab in respiratory syncytial virus disease (RSV) (2 arms), sponsored by MedImmune. Started Jul 2019; status: completed.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on jRCT2080224799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224799.